ArticleInternational journal of pharmaceutics: X2026
Development of hyaluronic acid-based nanocomposite eye drops: A synergistic platform for enhanced ocular delivery of acetazolamide.
Article in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The limitations of conventional therapeutic approaches for treating ocular diseases such as glaucoma via the topical administration route are nowadays a constant challenge for researchers in the field of pharmaceutical technology. The present study shows the feasibility of developing nanocomposite hydrogel-based eye drops for the topical delivery of acetazolamide, underlining its potential benefits in the glaucoma treatment. In detail, hyaluronic acid hydrogels loaded with acetazolamide nanocrystals were developed and characterized in accordance with requirements for ocular administration. Nanocomposite hydrogels composition was optimized with hyaluronic acid 1.25%
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.